Formulation and evaluation of herbal chocolate from Arjuna Bark- treatment of heart disease condition

Abstract

In the indigenous medical system, Terminalia arjuna is one of the most widely used and advantageous medicinal herbs for the treatment of cardiovascular disorders. This thorough analysis offers the most recent information on the traditional uses, phytochemistry, pharmacological data, toxicological data, clinical efficacy, safety and efficacy of Terminalia arjuna. It also lays out plans for further study and development to substantiate the plant's therapeutic potential through scientific means. A thorough web and library search of numerous indexed and non-indexed journals, some local literature and a variety of publications published on ethnopharmacology, phytochemistry and traditional usage were used to gather information about Terminalia arjuna. Regarding the effectiveness and safety profile of Terminalia arjuna, numerous pre-clinical (2000–2014) and clinical investigations (1990–2014) have also been taken into consideration. The pleiotropic advantages associated with Terminalia arjuna, comprising its anti-atherogenic, hypotensive, inotropic, anti-inflammatory, anti-thrombotic and antioxidant properties, have been demonstrated in numerous in vitro, in vivo and clinical investigations. These effects can be used to treat a variety of cardiovascular problems. There is sample evidence to support the plant's good safety profile when combined with other traditional medications. The precise molecular mechanism of its action, the best way to administer the medication, whether to employ an alcoholic, watery or crude extract, toxicological research and how it interacts with other medications are all poorly understood. This review concludes by emphasizing the significance of Terminalia arjuna, as well as its pleiotropic effects and functional characteristics particularly in relation to cardiovascular disorders. Even though a number of pharmacological research and clinical trials back up its traditional use in treating CVD, more rigorous, state-of-the-art clinical trials with larger sample sizes are necessary to evaluate Terminalia arjuna purported efficacy.